About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk: London, UK Tuesday, May 19, 2026, 12:00 Hrs [IST] GSK plc announced tha ...
Lupin received US FDA tentative approval for Revefenacin Inhalation Solution (175 mcg/3 mL), bioequivalent to Yupelri, ...
Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results